Abstract
Two cohorts of four subjects requiring hemodialysis received tefibazumab (10 or 20 mg/kg). The mean elimination half-life was between 17 and 18 days, the average volume of distribution was 7.3 liters, and the average clearance was 12 ml/h for both dose groups. At a dose of 20 mg/kg of body weight, plasma levels were 88 microg/ml at 21 days.
Publication types
-
Clinical Trial, Phase I
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adhesins, Bacterial / immunology*
-
Adult
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / pharmacokinetics*
-
Female
-
Humans
-
Kidney Failure, Chronic / therapy*
-
Male
-
Middle Aged
-
Renal Dialysis*
-
Staphylococcal Infections / therapy
-
Treatment Outcome
Substances
-
Adhesins, Bacterial
-
Antibodies, Monoclonal
-
clfB protein, Staphylococcus aureus